The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 4,187,050 |
| Payment of operating costs through promissory note | 77,799 |
| Interest earned on cash and investments held in trust account | 4,933,800 |
| Gain on extinguishment of over-allotment option liability | 553,748 |
| Provision for credit losses | 812,113 |
| Prepaid expenses | -16,766 |
| Due from sponsor | 812,113 |
| Accounts payable | 99,359 |
| Accrued expenses | 88,343 |
| Net cash used in operating activities | -1,018,231 |
| Investment of cash into trust account | 500,000,000 |
| Net cash used in investing activities | -500,000,000 |
| Proceeds from sale of units, net of underwriting discounts paid | 490,000,000 |
| Proceeds from sale of private placement units | 12,000,000 |
| Repayment of promissory note - related party | 533,781 |
| Payment of offering costs | 464,800 |
| Net cash provided by financing activities | 501,001,419 |
| Net change in cash | -16,812 |
| Cash beginning of period | 17,035 |
| Cash end of period | 223 |
Drugs Made In America Acquisition II Corp. (DMIIR)
Drugs Made In America Acquisition II Corp. (DMIIR)